Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Research on balomenib for type 2 diabetes is testing an unusual idea: treat for only a few weeks, then see whether better glucose control persists after the drug is stopped. That is the question raised by new Phase 1b results for balomenib, an investigational oral menin inhibitor from Clywedog Therapeutics. In the small randomized study, improvements in HbA1c and other glucose measures were reported weeks after the last dose. However, these findings remain early, company-reported results from 60 adults. Therefore, they should be viewed as a signal for further research rather than evidence of an established therapy.
Table of Contents
- Why menin inhibition is being studied
- What the Phase 1b trial found
- Why a lasting glucose effect would matter
- What comes next for balomenib
- Frequently asked questions
Why Menin Inhibition Could Change the Treatment Model
Most type 2 diabetes medicines work while a person continues taking them. Balomenib is being studied with a different goal: temporarily blocking menin in hopes of improving pancreatic beta-cell function. These cells make insulin, and declining beta-cell function plays an important role in the progression of type 2 diabetes.
Menin is involved in gene regulation and cell-cycle control. Meanwhile, experimental research suggests that inhibiting the menin pathway may encourage beta-cell replication under certain conditions. For example, research involving human pancreatic cells found that blocking the menin-MLL interaction, together with inhibition of the TGF-beta pathway, increased beta-cell replication without reducing insulin production.
However, laboratory findings do not prove that the same effect will occur safely or durably in people. That distinction is important because many promising biological mechanisms do not produce the same results in larger clinical trials. Therefore, the balomenib program in type 2 diabetes is testing whether a short intervention can produce metabolic benefits that continue after drug exposure ends.
What the Phase 1b Balomenib Trial Found
The randomized, double-blind Phase 1b study enrolled 60 adults with type 2 diabetes across three countries and assigned them to balomenib or placebo. Participants completed a four-week treatment period that included one week of dose titration. Afterward, researchers followed them for another 12 weeks without study treatment.
According to Clywedog's reported final Phase 1b results, the placebo-adjusted mean HbA1c reduction was 0.77 percentage points at Week 12 and 0.70 percentage points at Week 16. Importantly, Week 16 occurred about three months after the last dose. That persistence is one reason the findings have generated interest.
The company also reported a placebo-adjusted fasting plasma glucose reduction of 23 mg/dL at Week 12. In addition, oral glucose tolerance testing showed statistically significant improvements in several glucose measures at Day 85.
From a safety standpoint, Clywedog reported no drug-related serious or severe adverse events and no treatment-related discontinuations in the final company announcement. However, this was still a small, early-stage trial. It cannot establish long-term effectiveness, detect uncommon safety problems, or determine which patients are most likely to benefit.
As a result, these early balomenib findings should not be used to change current type 2 diabetes treatment decisions. Larger and longer studies are needed before clinicians can determine whether the reported effect is reproducible and clinically meaningful.
Why a Lasting Glucose Effect Would Matter
A glucose-lowering effect that continues after therapy stops would differ from the usual pattern of chronic diabetes pharmacotherapy. Most medications require ongoing use to maintain their benefits. In contrast, a short treatment course that produces persistent improvement could point toward a different therapeutic approach.
In theory, that durability might reflect an effect on beta-cell health or function rather than glucose lowering only while the medicine remains in the body. Still, the Phase 1b trial does not prove that beta-cell regeneration caused the reported HbA1c changes. That mechanism remains a hypothesis that future studies will need to test directly.
Moreover, the findings were reported by the drug developer and do not yet represent confirmation from a large, peer-reviewed Phase 2 or Phase 3 trial. Other menin inhibitors are also being investigated in diabetes, which adds scientific interest to the pathway. However, activity across the drug class does not confirm that balomenib will ultimately prove effective or safe.
Meanwhile, established therapies remain the foundation of individualized diabetes care. Patients should not stop, reduce, or replace prescribed medications because of these early findings. Anyone considering changes to diabetes treatment should discuss the decision with a qualified healthcare professional.
For now, research on balomenib in type 2 diabetes is best viewed as an early test of a potentially disease-modifying strategy. The idea is scientifically intriguing, but the evidence is not yet strong enough to determine whether the approach can alter the course of the disease.
What Comes Next for Balomenib in Type 2 Diabetes
Clywedog has said it plans a Phase 2a study using a longer 12-week balomenib treatment course, followed by another period of observation after treatment ends. That study should provide a stronger test of how large, consistent, and durable the glucose-lowering effect may be.
Future trials will also need to examine beta-cell function more directly. Measures such as C-peptide, insulin secretion, and glucose tolerance could help researchers determine whether menin inhibition is changing pancreatic function rather than simply producing an extended metabolic effect.
In addition, larger studies are necessary to identify less common adverse events and determine whether safety changes with longer exposure. Researchers will also want to know whether certain patient characteristics predict a stronger response. For example, disease duration, remaining beta-cell function, baseline HbA1c, and current medications could potentially influence treatment effects.
Even if the Phase 1b signal is repeated, describing balomenib as disease-modifying would require stronger evidence. Researchers would need to show that treatment changes the underlying course of type 2 diabetes rather than simply producing a prolonged period of better glucose control.
Consequently, the next stage of balomenib development for type 2 diabetes will focus on whether this unusual early signal can be reproduced convincingly in a larger population. Clywedog has said its Phase 2a study is expected to begin in the fourth quarter of 2026.
Conclusion
Balomenib presents a provocative idea for type 2 diabetes treatment: a relatively short course of therapy followed by glucose improvements that may continue after treatment ends. The early Phase 1b results support further investigation because HbA1c, fasting glucose, and oral glucose tolerance all moved in a favorable direction compared with placebo.
However, a 60-person early-stage study is only a starting point. The next trials must clarify the durability of the response, the biological mechanism involved, longer-term safety, and which patients may benefit most. Until those questions are answered, balomenib remains an investigational therapy rather than an alternative to established diabetes treatments.
Frequently Asked Questions
What is balomenib?
Balomenib, also known as ZE63-0302, is an investigational oral small-molecule inhibitor of menin. It is being studied for metabolic diseases, including type 2 diabetes.
Is balomenib approved for type 2 diabetes?
No. Balomenib remains an investigational drug and is not approved as a treatment for type 2 diabetes.
How long did the reported glucose improvements last?
Clywedog reported a placebo-adjusted HbA1c improvement at Week 16, which was about three months after participants received their final dose.
Does balomenib regenerate pancreatic beta cells?
That is part of the scientific rationale behind menin inhibition, but the Phase 1b clinical study did not prove that balomenib regenerated beta cells in humans. More research is needed to determine the mechanism behind the reported glucose improvements.
What happens next in balomenib research?
Clywedog has said it plans a Phase 2a study evaluating a longer 12-week course of treatment followed by an off-treatment observation period. That study should provide more information about efficacy, durability, beta-cell function, and safety.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.